Pediatric Lamisil granules get FDA nod
Lamisil oral granules are approved by the FDA for tinea capitis
Terbinafine (Lamisil, Novartis) oral granules have been approved for the treatment of tinea capitis in children aged four years and older. Novartis developed the new formulation in response to a written request from the FDA for the product. The granules can be sprinkled on food and are approved to be administered once daily for six weeks.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
